Natera Medical (NTRA) Amount of Cash per Share

Corporate emblem and logo of Natera, Inc. (NTRA)

Natera, Inc. (NTRA) is based on unique genomic data and proprietary DNA analysis. The estimated cash per share demonstrates current liquidity, with the value of 7.63 characterizing this level. Management's aggressive strategy ensures rapid revenue growth, while the focus on in-house R&D and patent protection eliminates the need for mergers with other players.

Natera Inc (NTRA): Cash per Single Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for Natera, Inc.

- market price and analyst price targets:
- market capitalization details:
- cash position and cash flow details:
Summary company analysis:NTRA Natera, Inc.
Manufactured product of Natera Inc

This indicator determines the volume of liquid assets per common share, allowing for an assessment of the internal capital cushion and investor protection. Analyzing the average cash per share reveals how explosive demand for Natera, Inc. (NTRA) oncology tests has transitioned the company from depleting reserves to self-funding via positive operating cash flow.